Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Public health policy and health economics

4132 - Real-World Productivity, Healthcare Resource Utilization (HRU), and Quality of Life (QOL) in Patients with Advanced Gastric Cancer (GC) in Canada and Europe


09 Sep 2017


Public health policy and health economics


Bioethical Principles and GCP;  Gastric Cancer


Gregory Maglinte


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


G. Maglinte1, A. Rider2, M. Contente3, A. Boyers2, B. Clarke2, E. Calvo4

Author affiliations

  • 1 Wwheor, Bristol-Myers Squibb, 08540 - Princeton/US
  • 2 Adelphi Real World, Adelphi Group, Manchester/GB
  • 3 Wwheor, Bristol-Myers Squibb, UB8 1DH - Uxbridge/GB
  • 4 Medical Oncology, START Madrid, Centro Integral Oncologico Clara Campal, Madrid/ES


Abstract 4132


As GC is the fifth most common cancer globally, it is important to better understand the impact of advanced disease on patient and caregiver productivity, HRU, and QOL.


Real-world data were collected through a cross-sectional survey administered to physicians and patients in France, Germany, Italy, Spain, the UK (EU5) and Canada (Nov 2016 to Mar 2017). Physicians provided patient data regarding disease history, characteristics, HRU, and caregiver burden. Health utility and overall health were assessed with the EQ-5D utility index (scores ranging 0 [dead] to 1.0 [full health]; scores


A total of 265 physicians provided information for 724 patients currently on their third line active drug treatment for advanced GC. The average age of patients was 63 years (50% ≥65 years), most were male (65%), with ECOG PS of 1 (39%) or ≥ 2 (55%), had gastric vs. gastroesophageal (GEJ; 68% vs. 31%) for primary site of disease, no prior gastrectomy (78%), and ≥2 organs with metastases (65%). Most patients (74%) were retired, unemployed, or on sick leave; of these patients, 30% were unable to work due to their GC. 39% of patients had caregivers spending an average of 47.6 hours of care/week (SD = 46.2). Many caregivers were partners/spouses (76%) who were unable to work or were working less in order to care for the patient (82%). Advanced GC also had an impact on HRU and EQ-5D scores. In the prior 12 months, patients made an average of 13.4 visits to an oncologist (SD = 8.1) and had 0.76 GC-related hospitalizations (SD = 2.34). Relative to EU5 general population norms for ages 65-74 (EQ-5D index, 0.78-0.90; VAS, 67.8-77.3), patients had worse health utility (mean EQ-5D index score=0.61; SD = 0.35) and overall health (mean VAS score=50.6; SD = 20.4).


As indicated by real-world data, advanced GC is associated with productivity loss for both patients and caregivers, significant HRU, and meaningful reductions in patients’ QOL. Novel treatment options are needed to reduce the overall burden of this disease.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Bristol-Myers Squibb


Bristol-Myers Squibb


G. Maglinte: Employee and stock holder of Bristol-Myers Squibb. M. Contente: Employee and stock option holder at Bristol Myers Squibb. E. Calvo: Consulting/Research funding/Speakers Bureau from various companies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.